TRC 101

Drug Profile

TRC 101

Alternative Names: TRC-101

Latest Information Update: 12 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Tricida
  • Class
  • Mechanism of Action Carrier protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Renal failure

Most Recent Events

  • 10 Jan 2017 Efficacy and adverse events data from a phase I/II trial in Chronic Kidney Disease released by Tricida
  • 10 Jan 2017 Tricida plans a phase III program for chronic kidney disease
  • 01 Nov 2016 Tricida completes a phase-I/II clinical trial in Renal failure (In adults, In the elderly) in Georgia and Bulgaria (PO) (NCT02809183)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top